Clinical Trial 55414

Nashville, TN 37211


Summary:

Ulcerative Colitis - Nashville TN
Click image to enlarge

AbbVie’s M21-446 study is evaluating the safety and effectiveness of an investigational oral medicine for adults with moderate to severe UC. This study does not include a placebo (inactive medicine). All participants will receive the study medicine, which is taken by mouth twice a day for four months (16 weeks).

Participants who qualify will participate in the study for about six months and will need to attend at least 11 study visits during this time. What happens at study visits will vary, but may include physical exams, endoscopies, ulcerative colitis assessments, blood draws, and other tests.



Criteria:
  • Are at least 18 years old
  • Have been diagnosed with UC for at least three months
  • Have had an inadequate response to, loss of response to, or intolerance to at least one treatment for UC (oral aminosalicylates, corticosteroids, immunosuppressants, and/or biologics or targeted immunomodulators)


Qualified Participants May Receive:

There is no cost to participate, and participants may receive compensation for time related to taking part in this study.


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.